Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference

Rhea-AI Summary

Ultragenyx Pharmaceutical (NASDAQ: RARE) announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. Dr. Emil Kakkis, the CEO, will engage in a fireside chat on June 11, 2024, at 10:00 a.m. ET. The event will be live-streamed and available for later viewing on Ultragenyx's investor relations website.

Positive

• Participation in a high-profile event increases visibility for Ultragenyx.
• CEO Dr. Emil Kakkis's involvement underscores the company's commitment to transparency and engagement with stakeholders.
• Live and archived webcasts provide accessibility for a broader audience, potentially attracting more investors.

Negative

• No new financial or clinical data was disclosed in the announcement, leaving investors without concrete updates.
• The press release does not mention any expected outcomes or strategic announcements from the conference.

NOVATO, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's chief executive officer, will participate in a fireside at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, at 10:00 a.m. ET.

The live and archived webcast of the panel will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contacts – Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com

Media
Carolyn Wang
media@ultragenyx.com

FAQ

What is the date and time of Ultragenyx's participation in the Goldman Sachs Healthcare Conference?

Ultragenyx will participate on June 11, 2024, at 10:00 a.m. ET.

Who will represent Ultragenyx at the Goldman Sachs Healthcare Conference?

Dr. Emil Kakkis, the CEO of Ultragenyx, will represent the company.

Where can I access the live and archived webcast of Ultragenyx's session at the Goldman Sachs Healthcare Conference?

The webcast will be accessible on Ultragenyx's investor relations website.